logo

Ultragenyx Pharmaceutical Inc (RARE)



Trade RARE now with
  Date
  Headline
6/10/2021 8:48:52 AM Ultragenyx, GeneTx Receive Approval From UK Regulatory Agency To Begin Clinical Study Of GTX-102
5/14/2021 8:37:18 AM Ultragenyx Reports Positive Multi-Year Durability Data From Ongoing Phase 1/2 Gene Therapy Studies
3/8/2021 8:34:18 AM Ultragenyx Announces FDA Clearance Of IND Application For UX053
2/11/2021 4:16:02 PM Ultragenyx Pharma Q4 Loss/share $0.37 Vs. Loss $1.62 Year Ago
1/8/2021 9:05:33 AM Ultragenyx: Durable Response Reported From Phase 1/2 Studies Of DTX401 For GSDIa And DTX301 For OTC
10/27/2020 10:28:52 PM Ultragenyx Pharma Q3 Loss Narrows
10/27/2020 4:20:41 PM Ultragenyx Q3 Net Loss $68.8 Mln Or $1.13/Shr Vs Loss $113.0 Mln Or $1.96/Shr Last Year
9/2/2020 8:14:42 AM Ultragenyx Appoints Mardi Dier As CFO
9/1/2020 8:37:44 AM Ultragenyx Appoints Ernie Meyer As EVP And Chief Human Resources Officer
7/30/2020 5:13:09 PM Ultragenyx Pharma Q2 EPS $0.41 Vs. Loss $1.72 Year Ago
7/22/2020 8:40:59 AM Ultragenyx Announces U.S. Commercial Launch Of Dojolvi For The Treatment Of Long-chain Fatty Acid Oxidation Disorders
5/6/2020 4:59:17 PM Ultragenyx Pharma Q1 Loss/share $2.05 Vs. Loss $1.82 Year Ago
3/16/2020 8:42:53 AM GeneTx And Ultragenyx Report First Patient Dosed In Phase 1/2 Clinical Trial Of GTX-102